Compare PERF & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PERF | CABA |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.4M | 200.2M |
| IPO Year | N/A | 2019 |
| Metric | PERF | CABA |
|---|---|---|
| Price | $1.81 | $2.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | 112.2K | ★ 3.0M |
| Earning Date | 10-28-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8.89 | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $66,900,999.00 | N/A |
| Revenue This Year | $16.39 | N/A |
| Revenue Next Year | $14.80 | N/A |
| P/E Ratio | $32.93 | ★ N/A |
| Revenue Growth | ★ 14.47 | N/A |
| 52 Week Low | $1.51 | $0.99 |
| 52 Week High | $3.44 | $5.46 |
| Indicator | PERF | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 47.74 | 48.03 |
| Support Level | $1.67 | $2.01 |
| Resistance Level | $1.75 | $2.69 |
| Average True Range (ATR) | 0.08 | 0.21 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 51.85 | 48.53 |
Perfect Corp is engaged in the beauty and fashion tech revolution, providing omni-channel integrated solutions. The company runs a hybrid business model of direct consumer business (B2C business) and enterprise business (B2B business). For B2C businesses, the company offers six mobile apps under the "YouCam" suite, along with one online editing service tool, YouCam Online Editor, featuring AI and AR technologies. For B2B businesses, the company offers AI and AR-powered solutions tailored for the beauty and fashion industry. Geographically, the company has a presence in the United States, Americas-other, France, Japan, and Others. The company generates the majority of its revenue from the United States.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.